Jennifer Navarre, NP
Family · Lafayette, LANPI 1518406644
Payments from drug & device makers
Across 210 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$531
- Lilly USA, LLC$473
- AstraZeneca$458
- Novo Nordisk$340
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$252
- Ardelyx, Inc.$225
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,248100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $531 |
| Lilly USA, LLC | 31 | $473 |
| AstraZeneca(2 entities) | 11 | $458 |
| Novo Nordisk | 14 | $340 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $252 |
| Ardelyx, Inc. | 15 | $225 |
| Paratek Pharmaceuticals, Inc. | 5 | $196 |
| Amgen | 7 | $182 |
| Abbott | 9 | $169 |
| Idorsia Pharmaceuticals US Inc | 3 | $135 |
| Exact Sciences | 8 | $134 |
| Amarin Pharma, Inc. | 7 | $118 |
| Bayer | 6 | $104 |
| Eisai Inc. | 5 | $92 |
| Dexcom, Inc. | 4 | $82 |
| Ironwood Pharmaceuticals, Inc | 5 | $82 |
| Astellas Pharma Global Development | 1 | $81 |
| Pfizer | 4 | $72 |
| Medtronic | 1 | $67 |
| Astellas Pharma US Inc | 4 | $67 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Edwards Lifesciences | 2 | $61 |
| Sanofi Pasteur Inc. | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Kyowa Kirin, Inc. | 1 | $25 |
| GSK | 1 | $21 |
| Merck | 1 | $20 |
| Biogen | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Silk Road Medical, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,248 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 51 | $95,283 |
| MounjaroTirzepatide | 32 | $51,126 |
| LinzessLinaclotide | 63 | $47,316 |
| OzempicSemaglutide | 31 | $37,387 |
| JardianceEmpagliflozin | 12 | $16,484 |
| JanuviaSitagliptin Phosphate | 14 | $15,006 |
| MyrbetriqMirabegron | 22 | $14,378 |
| VascepaIcosapent Ethyl | 12 | $9,845 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $9,274 |
| EliquisApixaban | 12 | $6,510 |
| BelsomraSuvorexant | 11 | $4,676 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $2,247 |
| Gabapentin | 125 | $1,572 |
| Diclofenac Sodium | 84 | $1,483 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $473 | $146,41083 claims |
| AbbVieLinzess | $531 | $47,31663 claims |
| Novo NordiskOzempic | $340 | $37,38731 claims |
| MerckJanuvia, Belsomra | $20 | $19,68325 claims |
| Boehringer IngelheimJardiance | $17 | $16,48412 claims |
| Astellas Pharma US IncMyrbetriq | $67 | $14,37822 claims |
| GSKAnoro Ellipta | $21 | $9,27418 claims |
| PfizerEliquis | $72 | $6,51012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.
Other family in Lafayette
- Rebekah GarrardLafayette$105K
- Jorge MenaLafayette$27K
- Amanda KeysLafayette$27K
- Shanna JohnsonLafayette$22K
- Layne LemaireLafayette$13K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.